SCHEMBL3875677

SCHEMBL3875677

CCC(=O)NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1Br

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TBK1 Q9UHD2 16/20 0.77
▸ MARK3 P27448 3/20 0.77
▸ MARK4 Q96L34 3/20 0.77
▸ STK17A Q9UEE5 3/20 0.77
▸ PDPK1 O15530 6/20 0.76
▸ CDK2 P24941 1/20 0.76
▸ ULK1 O75385 3/20 0.66
▸ PDK1 Q15118 3/20 0.66
▸ ULK2 Q8IYT8 3/20 0.66
▸ AURKA O14965 1/20 0.66
▸ NUAK1 O60285 2/20 0.62
▸ TYK2 P29597 2/20 0.62
▸ AAK1 Q2M2I8 2/20 0.62
▸ MKNK2 Q9HBH9 2/20 0.62
▸ STK16 O75716 1/20 0.62
▸ NTRK1 P04629 1/20 0.62
▸ CSNK2A2 P19784 1/20 0.62
▸ BMPR2 Q13873 1/20 0.62
▸ NUAK2 Q9H093 1/20 0.62
▸ BMP2K Q9NSY1 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13897664 0.94 TBK1 (0.75) TBK1MARK3MARK4STK17APDPK1
SCHEMBL13898146 0.92 TBK1 (0.78) TBK1MARK3MARK4STK17APDPK1
SCHEMBL13898107 0.92 TBK1 (0.75) TBK1MARK3MARK4STK17APDPK1
SCHEMBL13898109 0.92 TBK1 (0.77) TBK1MARK3MARK4STK17APDPK1
SCHEMBL13897707 0.92 TBK1 (0.77) TBK1MARK3MARK4STK17APDPK1
SCHEMBL13897784 0.92 TBK1 (0.79) TBK1MARK3MARK4STK17APDPK1
SCHEMBL13898279 0.91 TBK1 (0.74) TBK1MARK3MARK4STK17APDPK1
SCHEMBL13898235 0.91 TBK1 (0.74) TBK1MARK3MARK4STK17APDPK1
SCHEMBL13897849 0.91 TBK1 (0.74) TBK1MARK3MARK4STK17APDPK1
SCHEMBL13897985 0.91 TBK1 (0.74) TBK1MARK3MARK4STK17APDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504410-B2 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 2009-03-17 — — US claimed
US-20040186118-A1 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-09-23 — — US claimed
US-7504410-B2 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 2009-03-17 — — US disclosed
US-7504410-B2 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 2009-03-17 — — US disclosed
US-7504410-B2 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 2009-03-17 — — US disclosed
US-20040186118-A1 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-09-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186118-A1 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents DCK, PDPK1, DTYMK TBK1 452/4885MARK3 909/4885MARK4 873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback